12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Company News  |  Deals

Sequella, LabCorp deal

Sequella granted LabCorp a license to use B-SMART technology to develop and commercialize in the U.S. a laboratory-based antibiotic susceptibility assay for Mycobacterium tuberculosis. The assay...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >